FAAH Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

FAAH (Fatty-acid amide hydrolase) is an enzyme and a member of the serine hydrolase family. It is also an integral membrane hydrolase with a single N-terminal transmembrane domain. FAAH is responsible for the degradation of fatty acid amides, including the endocannabinoid anandamide, and for regulating palmitoylethanolamide with anti-inflammatory and analgesic properties. FAAH inhibitors selectively inhibit FAAH by displaying analgesic, anti-inflammatory, anxiolytic, and anti-depressive effects without causing any disruptions in motility, cognition, or body temperature. FAAH inhibitors are in the clinical investigative phases for post-traumatic stress disorders, anxiety disorders, pervasive child development disorders, and others. Jazz Pharmaceuticals, J&J, Autobahn Therapeutics, Astellas Pharma, BMS, Sanofi, Eisai, and Merck (MSD) are major players in the FAAH inhibitors market.

Key Market Developments:

• In May 2021, Autobahn Therapeutics acquired ASP 3652, FAAH inhibitor from Astellas Pharma.
• In Dec 2021, Jazz Pharmaceuticals JZP 150, a FAAH inhibitor received Fast Track designation for post-traumatic stress disorders in the USA.

Drugs under the Pipeline for FAAH Inhibitors:

• JZP150
• JNJ-42165279
• ASP3652
• ASP8477
• CC-97489
• SSR411298
• V158866
• BIA 10 2474
• IW-6118
• URB597

Clinical Activity and Developments of Fatty-acid amide hydrolase (FAAH) Inhibitors:

Currently, there are 10 drug products in the FAAH inhibitors, and all of them are in the clinical development phases.

• In Dec 2021, Jazz Pharmaceuticals initiated enrolment in a phase-II trial for post-traumatic stress disorders in the USA, for JZP 150, a FAAH inhibitor.
• In Oct 2022, Janssen Research & Development completed a phase-II trial in pervasive child development disorders in the USA for JNJ 42165279, a FAAH inhibitor.